Orchestra BioMed (NASDAQ:OBIO) Price Target Cut to $12.00 by Analysts at Barclays
Orchestra BioMed (NASDAQ:OBIO – Free Report) had its target price decreased by Barclays from $16.00 to $12.00 in a research note issued to investors on Monday,Benzinga reports. Barclays currently has an overweight rating on the stock. Several other equities research analysts have also issued reports on OBIO. Chardan Capital reiterated a “buy” rating and set […]
Orchestra BioMed (NASDAQ:OBIO – Free Report) had its target price decreased by Barclays from $16.00 to $12.00 in a research note issued to investors on Monday,Benzinga reports. Barclays currently has an overweight rating on the stock. Several other equities research analysts have also issued reports on OBIO. Chardan Capital reiterated a “buy” rating and set […]
